Journal
EPIGENOMICS
Volume 6, Issue 2, Pages 215-228Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/epi.14.12
Keywords
bromodomain inhibitor; chromatin; DNA methyltransferase inhibitor; histone deacetylase inhibitor; histone demethylase inhibitor; histone methyltransferase inhibitor; multiple myeloma
Categories
Funding
- Myeloma UK
- Cancer Research UK [12103] Funding Source: researchfish
Ask authors/readers for more resources
Despite recent advances in therapy, subgroups of multiple myeloma continue to have a poor prognosis. Numerous epigenetic changes have been described and occur as both etiologic and secondary events, making myeloma a good disease in which to understand the role of epigenetic therapies. Here, we describe a number of current and potential epigenetic targets in myeloma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
